119 related articles for article (PubMed ID: 35753784)
1. [Direct medical costs of Parkinson's disease by Hoehn and Yahr severity in Japan: An analysis of administrative claims data].
Baba K; Naoi I; Shibahara H; Inoue S; Aino H
Rinsho Shinkeigaku; 2022 Jul; 62(7):524-531. PubMed ID: 35753784
[TBL] [Abstract][Full Text] [Related]
2. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
3. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of deep brain stimulation in severe Parkinson's disease utilizing UPDRS III and modified Hoehn and Yahr as a severity scale.
Kahn L; Mathkour M; Lee SX; Gouveia EE; Hanna JA; Garces J; Scullen T; McCormack E; Riffle J; Glynn R; Houghton D; Lea G; Biro EE; Bui CJ; Sulaiman OA; Smith RD
Clin Neurol Neurosurg; 2019 Apr; 179():67-73. PubMed ID: 30851616
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
Shimbo T; Hira K; Takemura M; Fukui T
Pharmacoeconomics; 2001; 19(8):875-86. PubMed ID: 11596839
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
7. Costs of drug treatment in Parkinson's disease.
Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
[TBL] [Abstract][Full Text] [Related]
8. Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.
Zhang H; Zhou W; Zhang D
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328925
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment is associated with Hoehn and Yahr stages in early, de novo Parkinson disease patients.
Siciliano M; De Micco R; Trojano L; De Stefano M; Baiano C; Passaniti C; De Mase A; Russo A; Tedeschi G; Tessitore A
Parkinsonism Relat Disord; 2017 Aug; 41():86-91. PubMed ID: 28576605
[TBL] [Abstract][Full Text] [Related]
10. Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson's Disease.
Kashihara K; Kitayama M
Intern Med; 2023 Mar; 62(5):711-716. PubMed ID: 35945019
[TBL] [Abstract][Full Text] [Related]
11. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
Goetz CG; Poewe W; Rascol O; Sampaio C; Stebbins GT; Counsell C; Giladi N; Holloway RG; Moore CG; Wenning GK; Yahr MD; Seidl L;
Mov Disord; 2004 Sep; 19(9):1020-8. PubMed ID: 15372591
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease in Sweden-resource use and costs by severity.
Hjalte F; Norlin JM; Kellerborg K; Odin P
Acta Neurol Scand; 2021 Nov; 144(5):592-599. PubMed ID: 34254292
[TBL] [Abstract][Full Text] [Related]
13. Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study.
Toyama M; Okuma Y; Yamamoto M; Kashihara K; Yoshida K; Saiki H; Maeda T; Tsuboi Y; Takahashi Y; Nakayama T
J Neurol Sci; 2020 May; 412():116641. PubMed ID: 32151836
[TBL] [Abstract][Full Text] [Related]
14. [Practical guideline of Parkinson's disease in Japan: evaluation and mission of future].
Yamamoto M
Rinsho Shinkeigaku; 2013; 53(11):1352-3. PubMed ID: 24291986
[TBL] [Abstract][Full Text] [Related]
15. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
[TBL] [Abstract][Full Text] [Related]
16. Comparison of elderly and young patient populations treated with deep brain stimulation for Parkinson's disease: long-term outcomes with up to 7 years of follow-up.
Hanna JA; Scullen T; Kahn L; Mathkour M; Gouveia EE; Garces J; Evans LM; Lea G; Houghton DJ; Biro E; Bui CJ; Sulaiman OA; Smith RD
J Neurosurg; 2018 Sep; 131(3):807-812. PubMed ID: 30265192
[TBL] [Abstract][Full Text] [Related]
17. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
Prado M; Jamora RD
J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary.
Tamás G; Gulácsi L; Bereczki D; Baji P; Takáts A; Brodszky V; Péntek M
PLoS One; 2014; 9(9):e107704. PubMed ID: 25229404
[TBL] [Abstract][Full Text] [Related]
19. Clinical REM sleep behavior disorder and motor subtypes in Parkinson's disease: a questionnaire-based study.
Aygun D; Turkel Y; Onar MK; Sunter T
Clin Neurol Neurosurg; 2014 Apr; 119():54-8. PubMed ID: 24635926
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease: quantification of disability based on the Unified Parkinson's Disease Rating Scale.
Martínez-Martín P; Fontán C; Frades Payo B; Petidier R
Neurologia; 2000 Nov; 15(9):382-7. PubMed ID: 11195144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
